Ticker
ACHV

Price
5.20
Stock movement up
+0.21 (4.21%)
Company name
Achieve Life Sciences Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
93.06M
Ent value
97.55M
Price/Sales
-
Price/Book
89.14
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-30.11%
3 year return
-24.29%
5 year return
-55.62%
10 year return
-57.94%
Last updated: 2023-02-03

DIVIDENDS

ACHV does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book89.14
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count17.90M
EPS (TTM)-3.95
FCF per share (TTM)-3.26

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-37.05M
Net income (TTM)-38.27M
EPS (TTM)-3.95
EPS (1y forward)-2.27

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash18.20M
Net receivables145.00K
Total current assets20.96M
Goodwill1.03M
Intangible assets1.48M
Property, plant and equipment0.00
Total assets23.72M
Accounts payable6.89M
Short/Current long term debt0.00
Total current liabilities6.92M
Total liabilities22.68M
Shareholder's equity1.04M
Net tangible assets-1.47M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-31.62M
Capital expenditures (TTM)0.00
Free cash flow (TTM)-31.62M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-3665.61%
Return on Assets-161.32%
Return on Invested Capital-227.70%
Cash Return on Invested Capital-188.16%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open4.95
Daily high5.25
Daily low4.95
Daily Volume74K
All-time high1821600.00
1y analyst estimate24.75
Beta1.18
EPS (TTM)-3.95
Dividend per share-
Ex-div date-
Next earnings date8 Mar 2023

Downside potential

Loading...
Downside potential data
ACHVS&P500
Current price drop from All-time high-100.00%-13.68%
Highest price drop-100.00%-56.47%
Date of highest drop6 Jan 20239 Mar 2009
Avg drop from high-88.20%-11.49%
Avg time to new high93 days13 days
Max time to new high6370 days1805 days
COMPANY DETAILS
ACHV (Achieve Life Sciences Inc) company logo
Marketcap
93.06M
Marketcap category
Small-cap
Description
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Employees
16
Investor relations
-
SEC filings
CEO
Richard Alistair Balfour Stewart
Country
USA
City
Vancouver
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
SEATTLE, Wash and VANCOUVER, British Columbia, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
February 2, 2023
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and...
January 27, 2023
SEATTLE, Wash and VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
January 9, 2023
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q3 2022 Earnings Call Transcript November 14, 2022 Achieve Life Sciences, Inc. misses on earnings expectations. Reported EPS is $-1.35 EPS, expectations were ...
December 29, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development...
December 21, 2022
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported third quarter 2022 results in a press release and held a conference call aft...
November 21, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
November 15, 2022
Company to host conference call at 4:30 PM EST today, November 14, 2022SEATTLE and VANCOUVER, British Columbia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-sta...
November 14, 2022
Phase 2 ORCA-V1 Data Expected in 1H2023SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage clinical pharmaceutical...
November 8, 2022
SEATTLE, Wash and VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global develo...
October 31, 2022
Next page